868656-97-7

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indole-3-carboxylic acid, 6-bromo-, methyl ester is used as a precursor in the synthesis of bioactive molecules with diverse biological activities. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
1H-Indole-3-carboxylic acid, 6-bromo-, methyl ester is also used in the synthesis of agrochemicals, contributing to the development of new pesticides or other agricultural chemicals that can improve crop protection and yield.
It is important to handle 1H-Indole-3-carboxylic acid, 6-bromo-, methyl ester with care and follow proper safety protocols when working with it in a laboratory setting to ensure the safety of researchers and the environment.

Upstream product

• 101774-27-0 6-bromo-1H-indole-3-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 585-79-5 m-nitrobromobenzene 
• 24171-78-6 m-bromophenylhydroxylamine 
• 922-67-8 propynoic acid methyl ester 
• 771-50-6 1H-indole-3-carboxylic acid 
• 79878-02-7 1-(6-bromo-1H-indol-3-yl)-2,2,2-trifluoroethan-1-one 
• 67-56-1 methanol 
• 17826-04-9 6-bromo-1H-indole-3-carbaldehyde 
• 52415-29-9 6-bromo-1H-indole 

Downstream Products

• 1093631-89-0 methyl 6-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-3-pyridinyl]-1H-indole-3-carboxylate 
• 1093631-54-9 6-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-3-pyridinyl]-1H-indole-3-carboxylic acid 
• 1103500-20-4 TERN-101 
• 1103500-82-8 6-{4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

LACTAM COMPOUND AS FXR RECEPTOR AGONIST

Disclosed is a compound as shown in formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and the present invention relates to the use of same in the preparation of a drug for treating FXR-related diseases.

A general and scalable synthesis of polysubstituted indoles

A consecutive 2-step synthesis of N-unprotected polysubstituted indoles bearing an electron-withdrawing group at the C-3 position from readily available nitroarenes is reported. The protocol is based on the [3,3]-sigmatropic rearrangement of N-oxyenamines generated by the DABCO-catalyzed reaction of N-arylhydroxylamines and conjugated terminal alkynes, and delivers indoles endowed with a wide array of substitution patterns and topologies.

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a series of potent FXR agonists that robustly lower plasma LDL and vLDL in LDLr-/- mice. To this end the novel piperidinylisoxazole system LY2562175 was discovered. This molecule is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. The synthesis and biological profile of this molecule is discussed.

Total synthesis and biological studies of TMC-205 and analogues as anticancer agents and activators of SV40 promoter

TMC-205 is a natural fungal metabolite with antiproliferative activity against cancer cell lines. The light- and air-sensitivity prevented in-depth exploitation of this novel indole derivative. Herein, we report the first synthesis of TMC-205. On the basi

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceu

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

FXR AGONISTS

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.